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most difﬁcult ethical challenges our societies are facing. Objective: To
elicit through a discrete choice experiment the Belgian adult popula-
tion’s (18–75 years; N ¼ 750) preferences for prioritizing health care
and investigate whether these preferences are different for prevention
versus cure. Methods: We used a Bayesian D-efﬁcient design with
partial proﬁles, which enables considering a large number of attrib-
utes and interaction effects. We included the following attributes: 1)
type of intervention (cure vs. prevention), 2) effectiveness, 3) risk of
adverse effects, 4) severity of illness, 5) link between the illness and
patient’s health-related lifestyle, 6) time span between intervention
and effect, and 7) patient’s age group. Results: All attributes were
statistically signiﬁcant contributors to the social value of a health care
program, with patient’s lifestyle and age being the most inﬂuentialee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2014.12.007
yten@uantwerpen.be.
ondence to: Jeroen Luyten, Centre for Health Ec
Institute, Faculty of Medicine & Health Sciences,ones. Interaction effects were found, showing that prevention was
preferred to cure for disease in young adults, as well as for severe and
lethal disease in people of any age. However, substantial differences
were found in the preferences of respondents from different age
groups, with different lifestyles and different health states. Conclu-
sions: Our study suggests that according to the Belgian public,
contextual factors of health gains such as patient’s age and health-
related lifestyle should be considered in priority setting decisions. The
studies, however, revealed substantial disagreement in opinion
between different population subgroups.
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One of the greatest challenges for the future consists in ﬁnding a fair
match between ever-increasing medical needs and possibilities on
the one hand and ﬁnite health care budgets on the other hand.
Consensus exists that such priority setting should reﬂect a concern
for both efﬁciency (making maximal use of valuable resources) and
equity (avoiding that some people become deprived of their deserved
share) [1,2]. Over the past decades, the concern for efﬁciency has
been operationalized in cost-utility analysis, informing decision
makers on the ratio between incremental costs and incremental
quality-adjusted life-years (QALYs) attributable to interventions [3].
Equity, however, remains a much more elusive concept because a
large number of contextual considerations of patients, illnesses, or
interventions could justify a more or less favorable weighing in
rationing decisions [4]. Therefore, an important research objective
remains to clarify which distributive principles carry social support.The aim of this article is to contribute to the empirical
literature describing the general public’s distributive preferences
regarding health care. We do so by means of a discrete choice
experiment (DCE) held in a representative sample of the Belgian
adult population. We pay speciﬁc attention to the following two
issues. First, published studies about preferences for health care
resource allocation largely ignored the difference in nature
between prevention and cure. Unlike cure, however, prevention
1) avoids the intangible costs of experiencing ill-health; 2) can
give rise to substantial externalities, with consequences for both
efﬁciency and equity [5] (e.g., herd immunity through vaccination
[6]); 3) is closely related to social justice (e.g., by adjusting social
determinants of health) [7]); and 4) is attributed only a small
fraction (o5%) of the health care budget in most countries [8],
and may be the ﬁrst to be cut in times of scarcity. In this study,
we pay speciﬁc attention to the relative value of either type of
health care and investigate whether their nature affects rationingociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 2 4 – 2 3 3 225principles. Second, an important criticism against studies elicit-
ing social preferences is that aggregation covers up important
heterogeneity in the ethical views of different respondents [7].
We therefore pay much attention to differences in the prefer-
ences of relevant subgroups, via the inclusion of several respond-
ent characteristics as covariates in our analysis.Methods
DCEs are a widely used technique to quantify individuals’ prefer-
ences by observing their stated choices in a number of hypothetical
scenarios [9–11]. Respondents are confronted with a sequence of
choice sets consisting of two or more competing options. For each
choice set, they have to indicate the option they like best. The
options are described in terms of a ﬁxed set of attributes or
dimensions that differ in their levels. The data from a DCE allow
the assessment of the relative importance of each attribute in the
total value attributed to the options under valuation.
DCEs are predominantly used to elicit personal preferences
(for a general review of applications, see [12]), but, in a number of
studies, they have also been used to explore a population’s social
and ethical views regarding priority setting in health care (e.g.,
[13,14]; for speciﬁc reviews, see [15–17]). One motivation for using
DCEs in the latter context is that respondents are forced to
consider the consequences of their choice (choosing one option
implies foregoing the other), which avoids that they simply
ignore the fact that health care resources are limited.
Conducting a DCE involves the following steps: 1) identiﬁca-
tion of the attributes and attribute levels, 2) experimental design
of the choice sets, 3) survey development, 4) sample selection and
survey administration, and 5) data analysis.
Identiﬁcation of the Attributes and Attribute Levels
For our research objective, it was important to identify a number
of decontextualized, generic characteristics that provide a work-
able description of both preventive and curative interventions.
These characteristics should enable respondents to make a
meaningful judgment regarding the necessity to reimburse a
given intervention. We considered literature review and expert
opinion the preferable sources of information. Reviews have
classiﬁed considerations, potentially relevant for rationing health
care programs, into three groups: characteristics belonging to the
patient, the intervention, and the health condition [15,18]. We
updated a review of DCEs about priority setting [17] and identiﬁed
12 DCEs exploring the social value of health care [13,14,17,19–27].
We reviewed these studies focusing on the attributes used. We
observed that all studies used combinations of attributes to
indicate what would happen when a patient would not receive
care (severity of illness, expressed in morbidity and/or mortality)
and what would happen in case a patient received care (effective-
ness of the intervention/health improvement). In addition, the
studies involved a cost or budget impact attribute, the number of
patients affected, alternative treatment options, and character-
istics of the recipient (mainly age or health-related lifestyle).
The reviewed studies, however, mainly focused on cure,
either explicitly or implicitly by shaping a context that is
intuitively associated with curing patients, rather than with
preventing illness. Therefore, we carried out a separate review
of studies aiming to elicit preferences for prevention to ﬁnd
additional attributes. In a review of 114 DCEs [12], we found nine
speciﬁcally applied to preventive interventions such as screening
tests or vaccines [28–36]. These nine studies suggested the
inclusion of two additional attributes in our DCE, namely, the
intervention’s risk on adverse effects and the time span between
the intervention and its clinical effect.In sum, our literature review suggests the following list of
nine attributes as most useful to include in our DCE: type of
intervention (curative or preventive), effectiveness of the inter-
vention, adverse effects associated with the intervention, severity
of illness, cost of the intervention, number of patients, relation to
health-related lifestyle, time span between the intervention and
the expected effect, and age group of the patient.
Subsequently, we organized group discussions with conven-
ience samples consisting of researchers (N ¼ 10) and lay persons
(N ¼ 14) in which we presented interventions in terms of these
nine characteristics to investigate whether we overlooked poten-
tially important attributes and whether the descriptions we used
for the attributes and their levels allowed a realistic mental
image of a health care program. No additional attributes were
considered essential. However, when we tested exploratory
choice sets, it appeared that inclusion of all nine attributes made
the cognitive burden too large for respondents. Respondents not
only had to compare the characteristics of the intervention and
the disease but also had to consider scale differences between
both programs (cost and number of patients). This extra dimen-
sion required respondents to make calculations and made them
raise questions for clariﬁcation. Therefore, we decided to exclude
the attributes cost and number of patients by mentioning in
every choice set that the interventions had the same cost and
were beneﬁcial for the same number of patients.
The next challenge was to reﬁne the wording used to describe
the attributes and their levels, and to consider other than verbal
presentations of the attribute levels. First, we presented all
attributes to our convenience sample in various formulations to
determine which one was easiest to understand. Because the use
of attributes representing risks or chances is cognitively demand-
ing, we considered using visualizations for the levels of the
attributes effectiveness, risk on adverse effects, and lifestyle
instead of verbal descriptions [37]. However, we learnt that a
verbal description was most reliable because it minimized the
cognitive burden imposed on the respondents while still bringing
across the intended meaning. Also, for the other attributes, we
experimented by describing levels using numbers and percen-
tages, and found that the choice task was most intuitive when we
described levels verbally. Terms such as “rarely” and “often” are
more judgmental than numbers and chances (e.g., 1 adverse
effect per 100 interventions), and they may translate into differ-
ent numerical equivalents in different respondents. Using prob-
abilities, however, does not guarantee equal interpretation (e.g.,
is a chance of 1 per 100 rare or often?). For our purpose, the
qualitative rather than quantitative judgment of the respondent
was what mattered, and, therefore, we opted for qualitative
descriptions for a limited number of attribute levels.
We used three levels for each attribute, except for the
attributes type of intervention, which has two levels, and age
group of the patient, which has ﬁve levels. For the age attribute,
we decided against covering all ages because this would make the
age groups very wide. Instead, we opted for equally wide age
intervals at different stages of life. Table 1 presents the descrip-
tions of the attributes and their levels used. We presented the
attributes one by one to the members of our convenience sample
and asked them how they interpreted each attribute and attrib-
ute level. We encountered no difﬁculties in understanding.
Experimental Design of the Choice Sets
The DCE presented respondents with 14 choice sets of two
competing medical interventions, termed “proﬁles” henceforth.
The proﬁles are combinations of levels of the seven attributes in
Table 1. To limit the cognitive burden imposed on the respond-
ents, we used “partial proﬁles” [38–40]; that is, we varied the
levels of only four of the seven attributes in the choice sets and
Table 1 – Attributes and levels.
Attribute Level
What type of intervention is
it?
1. Preventive (aiming to prevent
healthy persons from
becoming ill)
2. Curative (aiming to cure
people who are ill)
How big is the probability of
success of the intervention?
1. 1 in 3 is successful (33%)
2. 2 in 3 is successful (66%)
3. Always successful (100%)
How often do adverse effects
occur?
1. Often
2. Rarely
3. Never
How severe is the illness for
which the intervention is
developed?
1. Not lethal, but everyone who
gets the disease will
experience a short period of
illness without lasting effects
(not severe)
2. Not lethal, but everyone who
gets the disease will
experience a severe and
lasting reduction in quality of
life (severe)
3. Lethal, everyone who gets the
disease will die from it (lethal)
Does the patient cause the
disease through his or her
own lifestyle?
1. Fully
2. Partly
3. Not at all
How long does it take before
the patient becomes ill/
shows signs/symptoms of
illness?
1. After 20 years
2. After 5 years
3. Within a year
At what age does the patient
become ill?
1. 80–90 years
2. 60–70 years
3. 40–50 years
4. 20–30 years
5. 0–10 years
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ent attributes are held constant across choice sets at levels that
change between choice sets. We did show the constant attributes
to the respondents. This improves the validity of the parameter
estimates on the one hand [41], and allows for the estimation of
interaction effects on the other hand. To facilitate the choice
tasks, we highlighted the varying attributes in each choice set.
Figure 1 shows an example choice set in which respondents had
to choose between two interventions A and B.
To maximize the information content of the DCE, we created
three different surveys by constructing a partial proﬁle design
involving 42 choice sets and dividing it into three groups of 14
choice sets such that each group or survey has a similar partial
proﬁle design structure (see below). In constructing the design
proﬁles, we excluded four unrealistic combinations of levels of
two attributes (shown in Appendix A in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2014.12.007 [which also
includes the three surveys]). We ensured that each survey was
ﬁlled out an equal number of times. As pointed out by Sándor and
Wedel [42], using 42 instead of 14 different choice sets results in a
larger amount of information on the respondents’ preferences
and therefore in more precise estimates of the relative impor-
tance of the attributes and attribute levels.
Besides the estimation of the main effects of the attributes, we
were interested in estimating the interactions between “type of
intervention” and any other attribute. However, because of the
disallowed level combinations associated with the attribute “timespan” (shown in Appendix A in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2014.12.007), the interaction between
“type of intervention” and “time span” cannot be estimated. As a
discrete choice model, we used a multinomial logit (MNL) model,
which is common practice in discrete choice design and analysis
[10]. The partial proﬁle design in Appendix A (in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.12.007) is D-
efﬁcient or D-optimal for the MNL model, meaning that it guaran-
tees precise estimates of the main effects and the interactions
between "type of intervention" and ﬁve other attributes [43].
Each choice set of the D-efﬁcient partial proﬁle design varies
the levels of four of the seven attributes. These varying attributes
differ from choice set to choice set. We determined them using the
attribute balance approach that attempts to vary each attribute in
an equal number of choice sets and to pair varying attributes an
equal number of times [39,40]. That is why each attribute is varied
in eight choice sets of each survey of the partial proﬁle design.
The D-efﬁcient partial proﬁle design takes into account prior
knowledge concerning the respondents’ preferences. For our DCE, for
example, it generally holds that the expected priority ranking for
reimbursement of interventions is, from low to high, related to a
mild disease, followed by a severe, but not lethal disease, and ﬁnally,
a lethal disease. Similarly, for all other attributes, we took into
account expert prior information about the most logical ordering of
the levels of the attributes, from low priority to high priority, the
result of which is presented in Table 1. We also ranked the attributes
in order of expected importance and expressed our uncertainty
regarding the a priori orderings of the attributes and attribute levels
in a multivariate normal prior distribution. In Appendix B (in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.12.007), we discuss in detail how we obtained that multivariate
normal prior distribution to optimize the design. The design that
maximizes the information content of the DCE (as measured by the
log-determinant of the information matrix; see [43]), when averaged
over that prior distribution, is called a Bayesian D-efﬁcient design.
The Bayesian D-efﬁcient design approach is increasingly considered
a state-of-the-art approach for DCEs (see, e.g., [43–48]; see also
Appendix C in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2014.12.007). Major beneﬁts of Bayesian D-efﬁcient designs
are that, using a proper prior distribution, they avoid choice sets in
which one proﬁle is completely dominating the other proﬁle(s) on
every attribute [49], and (as demonstrated below) such designs can be
constructed to efﬁciently estimate interaction effects.
Survey Development
We provided respondents with a Web link that allowed them to
carry out the choice tasks at their earliest convenience. To help
respondents, we presented a thorough explanation of the choice
tasks at the beginning of the DCE to familiarize them with 1) the
context of increasing scarcity in health care, the problem of
setting fair priorities, and our objective to investigate how the
general population thinks about this difﬁcult ethical policy issue
and 2) all seven attributes and their levels and how they are used
in the description of a treatment or a preventive intervention. We
asked respondents to choose between two interventions of which
only one could be reimbursed by the government.
After the DCE, we asked respondents a number of background
questions about their age, sex, height, weight, educational attain-
ment, family size, experience as health care worker, smoking
status, and experience with severe illness (personal or within the
family). To have an estimate of the respondents’ current health
state, the respondents also had to complete the EuroQol health
survey (i.e., the visual analogue scale [VAS] and the generic ﬁve-
level EuroQol ﬁve-dimensional questionnaire [EQ-5D-5L]) [50,51].
These are all variables that we a priori considered to be of
potential relevance to someone’s health care preferences.
A B 
What type of intervention is it? 
How big is the probability of success of the 
intervention? 
How often do adverse effects occur? 
How severe is the illness for which the 
intervention is developed? 
Does the patient cause the disease through his 
or her own lifestyle? 
How long does it take before the patient becomes 
ill/ shows signs/symptoms of illness? 
At what age does the patient become ill? 
YOUR PREFERENCE: 
Medical interventions A and B are exactly equally expensive and they apply to a similar number of patients. If you were forced to make a choice, which of 
both interventions should be reimbursed by the government? To make it easier for you, we have highlighted in yellow (gray in this figure) the characteristics 
that differ between both interventions. There are no right or wrong answers; we are interested in your opinion. 
Fig. 1 – Example of a choice set. Medical interventions A and B are exactly equally expensive and they apply to a similar
number of patients. If you were forced to make a choice, which of the two interventions should be reimbursed by the
government? To make it easier for you, we have highlighted in yellow (gray in this ﬁgure) the characteristics that differ
between both interventions. There are no right or wrong answers; we are interested in your opinion.
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In June 2012, a sample was drawn, representative of the Belgian
population in terms of age, sex, region, and educational attain-
ment, from an actively managed, continuously updated
panel of 10,753 Belgians. Participation was incentivized with
credits by means of which, after a number of positively
evaluated survey participations, gifts could be bought and a
lottery organized on a per-survey basis. Only one respondent
per household was allowed. The market research company
guarantees high-quality data through checks and ensures
that only “serious” respondents are included. To this end,
fraudulent, inattentive, hyperactive, or conditioned res-
pondents were removed from the sample, for example,
respondents who complete the survey unreasonably fast
(“speedsters”), consistently give the same answer (“straight-
liners”), and so on.
A total of 30% (N ¼ 3,160) of the 10,753 contacted individuals
agreed to participate, of which 937 were selected on the basis
of quota requirements. Of the selected individuals, 149 did
not ﬁnish the survey and 38 did not meet the quality criteria.
This left us with a sample of 750 respondents (250 respondents
for each of the three versions of the survey), and 10,500 observed
choices in total, that is, 14 per respondent. Respondents
were distributed proportionally over the three survey versions
according to language, sex, and age. Table 2 compares basic
characteristics of the sample to those of the population,
showing overall good agreement. Given the societal context
of this study, and a lack of clarity about the criteria (additional
to the ones described in the previous paragraph) that can
identify irrational response data in a DCE without imposing
preferences [52,53], all 750 respondents were included in our
analysis.Data Analysis
The data we collected through our DCE allow quantiﬁcation of and
statistical inference about the relative importance of the attributes
and attribute levels in assessing the priority ranking of a health
intervention. This is done by estimating the respondents’ utility
function as part of the MNL model, using a maximum likelihood
approach. The utility function is represented by the sum of the
utilities of the attributes’ main and interaction effects under study.
The overall signiﬁcance of the attributes was computed using
likelihood ratio (LR) tests, and the relative importance of the
attributes was measured by –log (P value of the LR test). We started
our analysis by estimating the a priori MNL model, that is, the
model that seemed most useful when planning the entire study
and which was used as a basis for constructing the D-efﬁcient
design for the DCE. That model includes the main effects of all
attributes and the interactions between type of intervention and
ﬁve other attributes. Next, we dropped the insigniﬁcant model
terms until we obtained a ﬁnal model in which all remaining
effects had signiﬁcant explanatory value. Preference heterogeneity
was assessed—in a separate analysis—by adding an interaction
term in the model with a variable that we a priori determined to be
of potential interest (e.g., sex or respondent’s age). We carried out
the entire data analysis using the Choice Modeling platform in the
statistical software package JMP 10.Results
Main and Interaction Effects
Figure 2 and Table 3 summarize the results of our analysis. All
seven attributes are statistically signiﬁcant contributors to the
Table 2 – Sample characteristics relative to those of
the Belgian population.
Characteristic Sample
(%)
Belgian
population (%)
Language
Dutch 56 56
French 44 44
Sex
Male (M) 50 50
Female (F) 50 50
Sex per age group*
18–24 M 6 6
18–24 F 6 6
25–34 M 9 9
25–34 F 10 9
35–44 M 10 11
35–44 F 10 10
45–54 M 10 10
45–54 F 11 10
55–64 M 9 8
55–64 F 10 8
65–75 M 6 6
65–75 F 4 6
Level of education†
None or lower education 8 19
Lower secondary
education
10 20
Higher secondary
education
31 33
Higher nonuniversity
education
35 18
University education 15 10
Province
Antwerp 15 16
West Flanders 10 11
East Flanders 13 13
Limburg 8 8
Hainault 13 12
Liege 10 10
Luxemburg 3 2
Namur 5 4
Brussels 10 10
Flemish Brabant 11 10
Walloon Brabant 3 3
Smoking status‡
Never smoked 45 54
Ex-smoker 30 22
Smoker 25 25
Source Belgian Data: Federale Overheidsdienst Economie [71].
* Age: The percentages reported are proportions in the selected
population (18–75 years), representing 71% of the total Belgian
population.
† Education: The percentages reported for the Belgian population
are for the age group 15 years or older. The percentages for our
sample are only for the age group 18 to 75 years. The over-
representation of higher educated respondents in our sample as
compared to the total population can be explained by our
exclusion of the group 15 to 18 years that is too young for higher
education, and the age group 75 years or older for which higher
education was less democratically accessible.
‡ Smoking percentages from the population are based on the
Scientiﬁc Institute of Public Health's 2008 Health Survey [72]
and are representative of the population aged 15 years or older.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 2 4 – 2 3 3228social value of a health care intervention, meaning that none of
them is considered irrelevant to priority setting. As shown in
Figure 2, the most inﬂuential attributes (based on the LR test) are
the patient’s health-related lifestyle and age. They are about
twice as important as the intervention’s effectiveness and about
four times as important as severity of illness. Type of interven-
tion is also an important attribute for the model because it
appears in two signiﬁcant interaction effects: between “type of
intervention” and “patient’s age” and between “type of interven-
tion” and “severity of illness” (see below). Its importance is
shown by the LR test for the joint signiﬁcance of the three effects
involving this attribute (LR χ2 ¼ 26.19; DF ¼ 7; P ¼ 0.0005). Time
span is the attribute that is least important.
The main-effect estimates in Table 3 represent the utilities
attached to the different levels of the attributes. The direction of
the coefﬁcients across the levels of each attribute is in line with
our a priori expectations. The attractiveness for reimbursement
increased as the intervention was more effective or had a lower
risk of adverse effects, when the disease was more severe or
occurred earlier in time, and when the patient’s age and the link
between the disease and the patient’s lifestyle was lower.
Figure 4 visualizes this for the two most inﬂuential attributes:
patient’s age and link with patient’s lifestyle (for the total sample
and for speciﬁc subgroups, see section Preference Heterogeneity).
Looking at the 95% conﬁdence intervals for the utility estimates
of each level, we judge that most coefﬁcients are different on a
statistically signiﬁcant level. In a few cases, the level estimates
did not signiﬁcantly differ: the adverse effects levels “never” and
“rarely,” the patient’s age levels “0-10 years” and “20-30 years,”
and the timing levels “within a year” and “after 5 years.”
In Figure 3, the two interactions involving type of interven-
tion are plotted. Our data suggest that the relative value of cure
versus prevention differed as a function of the age group of the
patient and the severity of the health problem. As shown in
Figure 3A, however, the interaction with age is mainly due to the
upward kink at 20 to 30 years in the value of prevention and the
downward kink at the same age category in cure. For patients
older than 30 years, the utility of prevention declined, whereas
the value of cure remained relatively stable over the age interval
from 20 to 70 years. However, we judge that this difference
in utility between prevention and cure in older age groups
is statistically not signiﬁcant because from the 95% con-
ﬁdence intervals we observe that the interaction effectsFig. 2 – Importance of the seven attributes (main and
interaction effects) to the social value of a health care
program relative to the most important attribute “Lifestyle of
Patient,” the importance of which is set to 100.
Table 3 – Estimates of coefﬁcients in the MNL model, their 95% CIs, and overall signiﬁcances of the attributes
using P values obtained from likelihood ratio tests.
Term Estimate 95% CI P
Lifestyle of Patient
Fully 0.3742 0.4324;0.3163 o0.0001
Partly 0.0483 0.0046;0.0921
Not at all 0.3259* 0.2685;0.3833
Age of Patient (years)
80–90 0.6160 0.7088;0.5241 o0.0001
60–70 0.0067 0.0829;0.0695
40–50 0.1168 0.0479;0.1857
20–30 0.2206 0.1485;0.2929
0–10 0.2853* 0.2012;0.3694
Effectiveness (%)
33 0.2584 0.3171;0.2001 o0.0001
66 0.0282 0.0177;0.0741
100 0.2302* 0.1765;0.2840
Severity of Illness
Not severe 0.2210 0.2946;0.1476 o0.0001
Severe 0.0653 0.0245;0.1061
Lethal 0.1557* 0.0812;0.2303
Adverse Effects
Often 0.1582 0.2131;–0.1037 o0.0001
Rarely 0.0856 0.0426;0.1287
Never 0.0726* 0.0235;0.1221
Type  Age of Patient (years)
Preventive  80–90 0.0120 0.0397;0.0638 0.0005
Preventive  60–70 0.0676 0.1190;0.0162
Preventive  40–50 0.0480 0.1038;0.0078
Preventive  20–30 0.1103 0.0537;0.1669
Preventive  0–10 0.0067* 0.0732;0.0600
Curative  80–90 0.0120* 0.0638;0.0397
Curative  60–70 0.0676* 0.0162;0.1190
Curative  40–50 0.0480* 0.0078;0.1038
Curative  20–30 0.1103* 0.1669;0.0537
Curative  0–10 0.0067* 0.0600;0.0732
Time Span
After 20 years 0.0843 0.1529;0.0155 0.0404
After 5 years 0.0234 0.0273;0.0741
Within a year 0.0609* 0.0069;0.1148
Type  Severity of Illness
Preventive  Not severe 0.0431 0.0801;0.0059 0.0487
Preventive  Severe 0.0345 0.0041;0.0731
Preventive  Lethal 0.0086* 0.0330;0.0503
Curative  Not severe 0.0431* 0.0059;0.0801
Curative  Severe 0.0345* 0.0731;0.0041
Curative  Lethal 0.0086* 0.0503;0.0330
Type
Preventive 0.0137 0.0297;0.0571 0.5376
Curative 0.0137* 0.0571;0.0297
CI, conﬁdence interval; MNL, multinomial logit.
* Coefﬁcient estimates corresponding to the last level of an attribute, either as main effect or involved in an interaction, are indicated in italic
to stress that they are calculated as minus the sum of the estimates for the other levels of that attribute. To illustrate, the value of 0.0086 for
the interaction effect Type [preventive]  Severity of Illness [lethal] is obtained as –(–0.0431 þ 0.0345).
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[preventive]  age of patient [60–70 years]” belong to each
other’s conﬁdence interval. Regarding the second interaction,
Figure 3B shows that severity of illness had a larger impact on
the utility of a preventive intervention than on that of a curative
one. Prevention was valued less than cure in case of a non-
severe, transient illness. However, it was valued more for severe,
long-lasting, and life-threatening diseases. Our respondents did
not consider effectiveness, risk of adverse effects, or lifestyle tobe of differential importance in choosing between prevention
and cure (i.e., these attributes did not interact with type of
intervention).Preference Heterogeneity
We found many differences in the preferences of various sub-
groups (indicated by a statistically signiﬁcant interaction effect).
The largest interactions (based on the LR test) were found
Fig. 3 – Marginal utility values for different combinations of “Age of Patient” and “Type of Intervention” (A) and for different
combinations of “Severity of Illness” and “Type of Intervention” (B).
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respondent’s smoking status and patient’s lifestyle.
Respondent’s age
Younger respondents attributed signiﬁcantly more importance to
patient’s age (P o 0.001), severity of illness (P o 0.001), and
patient’s lifestyle (P ¼ 0.0001). To visualize the impact of the
respondent’s age, we partitioned the respondents of our data set
into three age groups: 18 to 35 years, 36 to 60 years, and 61 to 75
years (see Fig. 4). For the youngest respondents, the social value
of an intervention depended more strongly on the patient’s age
(Fig 4A, dotted line) and the link between the disease and the
patient’s lifestyle (Fig 4B, dotted line) than for the older
respondents.
Sex
The covariate sex appeared in two signiﬁcant interactions, one
involving the attribute patient’s age (P ¼ 0.003) and one involving
the attribute effectiveness (P ¼ 0.01). Female respondents
attached less value to interventions for older patients than did
male respondents. Male respondents attributed a higher value to
effectiveness.Fig. 4 – Marginal utility values for the attributes “Age of Patient” (
population) and for different respondent subgroups (respondents
having an “unhealthy” lifestyle [i.e., being smoker or obese]).Level of education and experience in health care
Respondents with a degree of higher education (university or
nonuniversity) were more willing to ration on the basis of age
(P o 0.001) and attribute more importance to severity of illness
(Po 0.0001). In addition, they attributed more value to prevention
(P ¼ 0.02). No differences in opinion were found between higher
and lower educated respondents for the attributes lifestyle,
effectiveness, and adverse effects. Present or past experience as
health care worker (14% of the sample) did not result in signiﬁ-
cant interactions.
Household
The larger the household of the respondent, the more prevention
was preferred to cure (P ¼ 0.003) and the more the value of health
care decreased as a function of patient’s age (P ¼ 0.002).
Respondents living with children gave more importance to
patient’s age. No signiﬁcant interactions were found with other
attributes.
Health state
We found signiﬁcant interactions with the respondent’s VAS and
EQ-5D-5L scores. The lower the VAS score, the lower theA) and “Lifestyle of Patient” (B) for the entire sample (general
aged 18–35 years, aged 60–75 years, and a group deﬁned as
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 2 4 – 2 3 3 231importance of the patient’s age group (P o 0.0001) and the
stronger the preference for cure over prevention (P o 0.008).
The lower their EQ-5D-5L score, the more likely respondents were
to prefer cure over prevention (P o 0.006) and to prefer current
health gains over future ones (P o 0.01). Respondents who
reported having had personal experience with severe illness
attached greater value to cure than to prevention (P o 0.002),
and to current rather than to future health gains (P o 0.01). They
attributed less importance to adverse effects (P o 0.04) and were
less inclined to take the age of patients into account (P o 0.006).
We also partitioned our sample into a “good health” group (74% of
the sample) and a group with “present or past health problems”
(26%), depending on whether they had personal experience with
severe illness or had an EQ-5D-5L score below 0.6 or a VAS score
below 60. Both groups differ in that the “good health” group
preferred prevention (P o 0.002), discounted future health gains
to a lesser extent (P ¼ 0.04), and was more willing to ration on the
basis of age (P ¼ 0.01). Respondents’ choices did not differ
signiﬁcantly on the basis of experience with severe illness in
their family.
Lifestyle
Whether or not the respondent is a smoker is a highly inﬂuential
covariate and, hence, an important factor explaining preference
heterogeneity among the respondents. Smokers clearly attributed
a lower importance to the attributes lifestyle (P o 0.0001) and
patient’s age (P ¼ 0.0008), preferred cure to prevention (P o
0.0001), and discounted future health gains to a greater extent
(P ¼ 0.04). Also, “Body Mass Index” (BMI) turns out to be an
important covariate. The higher the BMI score, the less a
respondent takes into account the patient’s age (P o 0.0032),
severity of illness (P ¼ 0.0006), and the disease’s link with lifestyle
(P ¼ 0.04) and the more he or she prefers cure to prevention (P ¼
0.0034) and discounts future health gains (P ¼ 0.008). To visualize
the differential valuation by respondents with a “healthy” life-
style and patients with an “unhealthy” lifestyle, we partitioned
the respondents into two groups, one group (in total 38% of the
sample) containing respondents with a BMI exceeding 30 (i.e., the
obesity threshold [54]) as well as smokers and one group con-
taining nonsmokers with a BMI lower than 30. The “unhealthy”
lifestyle group preferred cure to prevention (P o 0.0001), attrib-
uted a lower weight to lifestyle (Po 0.0001) and patient’s age (Po
0.0001) (as illustrated in Fig. 4B), and, remarkably, attached more
importance to the risk of adverse effects (P ¼ 0.02).Discussion
The objective of our study was to investigate on which basis the
Belgian population wants to set health care priorities. Although
characteristics of the intervention (effectiveness and risk of
adverse effects) and of the illness (severity of illness and time
span) were found to matter, it were mainly the characteristics of
the recipient that drove respondents’ preferences. Priority was
given to younger patients and to those who have not somehow
caused their own illness. We also detected substantial hetero-
geneity in the preferences: young, healthy, highly educated or
more health-conscious adults responded in a markedly different
way than did older, unhealthy, less well educated, and health-
unconscious ones.
Our results conﬁrm studies in other countries indicating that
the context shapes the social value of QALYs, and that the
general public’s distributive preferences diverge from a
simple health maximization approach, as would be prescribed
by cost-utility analysis (i.e., minimizing cost/QALY) (e.g.,
[13,14,16,17,19,20,24,25,55]; for reviews, see [15,16,56]). Many of
these studies also observe a public preference for prioritizingyounger patients over older ones, and several ones describe how
a substantial number of participants want to account for self-
inﬂicted illness. However, our results seem to diverge from these
other studies in the strong impact of the lifestyle attribute, and
the relatively limited impact of severity of illness to priority
setting.
We paid speciﬁc attention to the difference between prevention
and cure. A few studies in the literature also compared stated
preferences for both types of health care [24,57–62]. These studies
found no preference [57,58], a preference for prevention [24,60,61],
or a preference for cure [59,62]. Our sample valued prevention
higher than cure only when it is targeted at relatively young age
groups and when it protects against more severe illness. However,
as the self-inﬂicted nature of a health condition was a factor of
major relevance in our study, indirectly, our results can be inter-
preted as providing further support for prevention in general. An
allocation scheme that accounts for individual responsibility would
mainly ration on curative treatments because accountability for
lifestyle is less relevant for (not) providing prevention, especially
when it comes to primary prevention. Preventive programs can
incentivize, or even enable, citizens to adopt healthy and responsible
lifestyles before their lifestyle-associated risk exposure requires
cure. Currently, preventive “lifestyle” policies such as alcohol, fat,
sugar, or smoking taxes are gaining interest [63,64]. Such measures,
if effective, would increase short-term government income and
reduce lifestyle-related morbidity.
Some limitations of our study must be mentioned. First and
foremost, priority setting in health care requires societal support
[65]. But the majority is not necessarily right [66,67]. We observed
that the support for age-based rationing and accounting for lifestyle
depends on the age and lifestyle of the respondents themselves,
indicating some degree of self-serving answers. Although we
conveyed to respondents to answer as citizens (a societal view)
and not as potential health care consumers (an individual view),
and although self-serving answers are not necessarily unjust, this
does raise suspicion of partiality. How this can be avoided, and how
we can construct a more effective “veil of ignorance” in social
preference studies, remains a challenge for further research. But
even with impartial answers, age-based rationing and accounting
for lifestyle remain controversial grounds for setting priorities (for
an elaborate discussion, see [68]). The results of public opinion
research in this area should always be complemented by ethical
considerations. Therefore, instead of being directly useful to
priority-setting decisions, our survey in the ﬁrst place supports
the need for a more extensive public debate about the appropriate
role of age and lifestyle in health care rationing.
Second, although our sample was broadly representative of the
Belgian population, respondents were recruited from an online
panel. This excluded respondents older than 75 years and member-
ship of the panel may be associated with unobservable character-
istics. Third, we surveyed our sample on a complex topic, in a single
recording. We encouraged respondents to think thoroughly about
their answer, and evidence suggests that respondents’ answers to
DCEs such as ours are reliable [21]. Nonetheless, it would be
interesting to repeat this study in a nonpanel sample (e.g., gen-
erated through random digit dialing of telephone numbers), and to
organize a follow-up study in the same sample to compare the
results. Fourth, an inherent limitation of DCEs is that only a limited
number of attributes can be used. Although we included a relatively
large number of attributes, the choice alternatives we presented
remain simpliﬁed versions of real health care programs. Fifth,
because this simpliﬁed the choice tasks, we excluded the cost
attribute. A disadvantage of this was that it became impossible to
quantify willingness to pay for changes in the attributes levels. Such
inferences, however, were not our primary objective, and, more-
over, they have also been shown to be less informative than
expected on some occasions [69,70].
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